SHUKRA
PHARMACEUTICALS LTD.

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street,
Mumbai-400001

04th June, 2025

Scrip Code: 524632

Dear Sir/Madam,

Sub: Outcome of the meeting of the Board of Directors held on Wednesday, June 04, 2025

Ref: Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, the Board of Directors of the at their meeting held on today i.e. Wednesday, June 04, 2025 at the Registered Office of the Company ***inter-alia*** has, considered and approved the following: -

1. The Board recommended a Final Dividend of Rs. 0.01/- (1%) per equity share of Rs. 1/- each fully paid (subject to deduction of tax, if any) for the financial year 2024-25. This shall be paid subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.

2. Reviewed the other Business of the Company.

The Board Meeting commenced at 04.00 p.m. and concluded at 4.30 p.m.

You are requested to take the above information on records.

Thanking you,

Yours faithfully

For Shukra Pharmaceuticals Limited

Shukra Pharmaceuticals Limited REG.NO.: 019079

Bpatel

Bhoomiben Patel
Director
DIN: 08316893